2023 international evidence-based guideline pcos glp-1 receptor agonist PDF) Recommendations from the for the assessment and management of polycystic ovary syndrome Research progress on insulin resistance

Empagliflozin in patients with chronic kidney disease

Only patterns that are representative of all published studies in this category have contributed to the conclusions summarized in this table

Authorities are monitoring how these drugs are being used across different care settings, including telehealth platforms and direct-to-consumer models

Phase 2 trials published in the New England Journal of Medicine showed the 12 mg dose group losing 24.2% of body weight at 48 weeks

Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes

This new avenue has yet to see a standout success, with Orforglipron emerging as a leading contender, showing promising results in blood sugar control and weight management according to clinical trials [14][15]